Cart
sales@molnova.com
Bay 59-3074
CAS No. 406205-74-1
Bay 59-3074( Bay59-3074 | Bay-59-3074 )
Catalog No. M14399 CAS No. 406205-74-1
A potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 28 | In Stock |
|
| 25MG | 48 | In Stock |
|
| 50MG | 77 | In Stock |
|
| 100MG | 144 | In Stock |
|
| 200MG | 214 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameBay 59-3074
-
NoteResearch use only, not for human use.
-
Brief DescriptionA potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively.
-
DescriptionA potent, selective cannabinoid CB1/CB2 receptor partial agonist with Ki of 48.3, and 45.5 nM for human CB1 and human CB2 receptors, respectively; displays antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic; orally acitve.
-
In Vitro——
-
In VivoBAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain. Animal Model:Male Wistar rats (160-250 g) Dosage:0.3 mg/kg, 1 mg/kg, and 3 mg/kg Administration:Oral administration; daily; for 2 weeks.Result:Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased.
-
SynonymsBay59-3074 | Bay-59-3074
-
PathwayGPCR/G Protein
-
TargetCannabinoid Receptor
-
RecptorCB1|CB2
-
Research AreaCancer
-
Indication——
Chemical Information
-
CAS Number406205-74-1
-
Formula Weight453.3555
-
Molecular FormulaC18H13F6NO4S
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 34 mg/mL
-
SMILESO=S(CCCC(F)(F)F)(OC1=CC=CC(OC2=CC=CC(C(F)(F)F)=C2C#N)=C1)=O
-
Chemical Name1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl ester
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Tetrahydrocannabivar...
Tetrahydrocannabivarin is a neutral cannabis receptor subtype (CB1) receptor antagonist, it can increases neural responding to rewarding and aversive stimuli, this effect profile suggests therapeutic activity in obesity, perhaps with a lowered risk of depressive side effects. Tetrahydrocannabivarin exhibits anticonvulsant effects in a piriform cortical brain slice model of epileptiform activity.
-
CB2R/FAAH?modulator-...
CB2R/FAAH modulator-2 (compound 26) is a dual modulator targeting CB2R and FAAH, acting as a CB2R agonist (Ki = 10.8 nM) and FAAH inhibitor (IC50 = 6.2 μM), with a Ki value of 152.9 nM for CB1R.
-
Drinabant
Drinabant is an orally active CB1 receptor antagonist. Drinabant inhibits the agonist-stimulated calcium signal with IC50 values of 25 nM and 10 nM for the hCB1-R and rCB1-R, respectively, and is ineffective for the hCB2-R.
